We have recently shown that targeting a catalytically inactive Cas9 fused to an activating VPR domain (CRISPRa) to an enhancer element at the 2q35 breast cancer risk locus increases expression of IGFBP5 (mapping ~400 kb distal) but neither of the neighbouring genes IGFBP2 and RPL37A (~460 kb and ~600 kb, respectively) [99]. This evidence concerns the gene IGFBP5 and breast cancer.